NIAID: Gilead’s Remdesivir Shows Positive Proof of Concept in Hospitalized COVID-19 Patients

The preliminary findings also showed a mortality rate of 8.0% for the patient cohort treated with remdesivir, vs. 11.6% for the placebo group, a difference that according to NIAID suggested a survival benefit to the Gilead nucleotide prodrug.